Forecast
The analysts' average price target is âŹ100.77 (+419.97%). The median is âŹ132.02 (+581.22%).
| Buy |
Â
5 |
| Hold |
Â
0 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Bright Minds Biosciences raises $175 million through placement of common shares
Bright Minds Biosciences placed 1,945,000 common shares at $90.00 each, generating gross proceeds of $175.05 million. The syndicate banks were granted a 30-day overallotment option for up to 291,750 additional shares. The funds are intended to finance clinical trials (including the start of phase 1 for BMB-105), research and development of earlier programs, and general corporate purposes. » More on de.investing.com
Bright Minds Biosciences sets price for share offering at $90
Bright Minds Biosciences has set the price for a public offering of 1,945,000 common shares at $90.00 per share and expects gross proceeds of about $175.05 million. The underwriters were granted a 30-day option to purchase up to 291,750 additional shares at the same price; closing is expected on January 9, 2026. The proceeds are intended to fund clinical trials for several drug candidates; the company has simultaneously ended its at-the-market program. Analysts mostly rate the stock as "Buy," and the share price and market capitalization have risen sharply after a strong rally. » More on de.investing.com
Bright Minds Biosciences plans public offering of $100 million
Bright Minds Biosciences announced a public offering of common stock and pre-funded warrants totaling $100 million and granted the underwriters a 30-day option to purchase up to 15% of the offered common stock. Proceeds are intended to fund clinical trials for drugs targeting absence seizures, DEE and PraderâWilli syndrome, as well as Phase 1 studies for BMBâ105, earlier-stage research and general corporate purposes. The offering is being made under an F-3 registration; Jefferies, TD Cowen, Piper Sandler and Cantor are serving as joint book-running managers. The company reports a strong balance sheet with more cash than debt and a current ratio of 36.1. » More on de.investing.com
Bright Minds Biosciences stock rises after positive phaseâ2 data on BMBâ101
The stock of Bright Minds Biosciences rose about 5% after positive topline results from the phaseâ2 BREAKTHROUGH study of the selective 5âHT2C agonist BMBâ101 in epilepsyâassociated disorders. In the 24âpatient study, median seizure frequency in absence epilepsy fell by 73.1% (p=0.012) and severe motor seizures in DEE patients by 63.3%. BMBâ101 also significantly improved REM sleep, was mostly well tolerated and showed no treatmentârelated serious adverse events. Bright Minds is preparing global registration trials for DEE and absence epilepsy and plans a study in PraderâWilli syndrome in Q1 2026. » More on de.investing.com
Bright Minds launches PraderâWilli program and nominates BMB-105 as clinical candidate
Bright Minds has launched a PraderâWilli syndrome (PWS) program and nominated BMB-105 as a new clinical candidate. The company is starting the doubleâblind, randomized phaseâ2a NOVA study with BMB-101 to evaluate efficacy and safety in PWS patients and plans a parallel randomized, placeboâcontrolled phaseâ1 study of BMB-105 in healthy volunteers. BMB-101 has shown good tolerability so far in epilepsy studies, with topâline data expected in January 2026; Bright Minds aims to accelerate time to market by roughly one year with BMB-105. » More on de.investing.com
Financials
In the last quarter, BRIGHT MINDS BIOSCIENCES had revenue of âŹ0 and net profit of -âŹ1.52m
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -12.32k | - |
| Net profit | -1.52m | 53.56% |
| EBITDA | -7.22m | 121.62% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | âŹ189.68m |
Number of shares | 9.86m |
52-week high/low | âŹ112.67 - âŹ15.84 |
| Dividends | No |
Beta | 0.09 |
P/E ratio | -9.97 |
PEG ratio | 0.13 |
P/B ratio | 0.92 |
P/S ratio | 0.00 |
Company profile
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
| Name | BRIGHT MINDS BIOSCIENCES |
| CEO | Ian McDonald |
| Headquarters | New York,
ny Canada |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 22/03/2021 |
| Employees | 26 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | DRUG |